Global Bioprocess Validation Market Size, Share & Industry Analysis Report By Mode (In house and Outsourced), By Stage (Continued Process Verification, Process Qualification, and Process Design), By Testing Type, By Regional Outlook and Forecast, 2025 - 2032

“Global Bioprocess Validation Market to reach a market value of USD 994 Million by 2032 growing at a CAGR of 8.8%”

Analysis of Market Size & Trends

The Global Bioprocess Validation Market size is expected to reach USD 994 million by 2032, rising at a market growth of 8.8% CAGR during the forecast period.

The global bioprocess validation market has changed from a qualification activity that happens after development to an integrated, lifecycle-driven field that is shaped by regulatory expectations, new technologies, and new biopharmaceuticals. Validation used to focus on static, batch-level checks. Now, it focuses on risk-based approaches, continuous monitoring, and data-driven oversight. New technologies like single-use systems, continuous bioprocessing, and real-time analytics have changed the requirements, making it necessary to validate disposables, extractables, leachables, and modular systems. The FDA and EMA have pushed for lifecycle and risk-based frameworks, while OEMs and service providers are using digital platforms, simulation tools, and process analytical technologies to make validation faster and more proactive. The market is also growing because biopharma companies are expanding in Asia-Pacific and outsourcing is becoming more common. CDMOs and specialized service providers are taking on bigger roles.

Some important trends are digital and continuous validation through predictive modeling, real-time sensors, and cloud-based analytics; full validation for single-use technologies; and more outsourcing to CDMOs and specialized companies. To meet local regulatory needs, top players use strategies like adding validation to hardware offerings, bundling services, and expanding into new areas. The competitive landscape balances large OEMs like Sartorius, Pall, and Thermo Fisher, who use their global reach and integrated solutions to their advantage, with agile, specialized validation providers who compete on speed, flexibility, and niche expertise. As validation becomes more digital, risk-based, and ongoing, companies that combine regulatory credibility with new ideas and scalable service models will be able to stay ahead of the competition in a market that is both growing and fragmented.

COVID 19 Impact Analysis

The COVID-19 pandemic hurt the bioprocess validation market because it messed up global supply chains, delayed transportation, and made it harder to get raw materials and equipment. Lockdowns and social distancing made it harder for people to work, which slowed down validation activities and pushed back product development. Because of the focus on COVID-19 treatments and vaccines, there was less need for validation in other parts of the pharmaceutical industry. Also, because of uncertainty in the economy, companies cut back on their R&D and compliance budgets, which delayed validation projects and made it take longer to get to market. In general, these things caused problems with operations, lower sales, and a slower growth rate for the market during the pandemic. Thus, the COVID-19 pandemic had a negative impact on the market.

Market Share Analysis

The leading players in the market are competing with diverse innovative offerings to remain competitive in the market. The above illustration shows the percentage of revenue shared by some of the leading companies in the market. The leading players of the market are adopting various strategies in order to cater demand coming from the different industries. The key developmental strategies in the market are Acquisitions, and Partnerships & Collaborations.

Stage Outlook

Based on Stage, the market is segmented into Continued Process Verification, Process Qualification, and Process Design. The process qualification segment recorded 31% revenue share in the bioprocess validation market in 2024.  This stage focuses on demonstrating that bioprocess equipment, systems, and utilities consistently perform within predefined acceptance criteria. It is a critical step in bridging the gap between process design and large-scale production, ensuring that the established parameters hold true under operational conditions.

Testing Type Outlook

Based on Testing Type, the market is segmented into Bioprocess Residuals Testing, Extractables & Leachables Testing, Viral Clearance Testing, Wireless and IoT Penetration Testing, and Other Testing Type. The extractables & leachables testing segment acquired 25% revenue share in the bioprocess validation market in 2024.  The increased reliance on single-use systems, disposable bioreactors, polymer-based tubing, and packaging materials in modern biomanufacturing has heightened concerns about potentially harmful substances leaching into final products.

Regional Outlook

Region-wise, the bioprocess validation market is analyzed across North America, Europe, Asia Pacific, and LAMEA.  The North America segment recorded 40% revenue share in the bioprocess validation market in 2024. North America and Europe have the biggest share of the global bioprocess validation market because their biopharmaceutical industries are well-established, their regulatory frameworks are strict, and their manufacturing infrastructure is advanced. The United States is the leader in North America because it has strong FDA oversight, a lot of biopharma companies, and a lot of money going into new treatments like monoclonal antibodies, vaccines, and cell and gene therapies. With the help of the EMA's lifecycle-based validation guidelines, Europe has become a center for regulatory-driven innovation. Countries like Germany, Switzerland, and the UK have major biopharma clusters. Both areas put a lot of emphasis on compliance, risk-based validation, and continuous monitoring. This makes there a lot of need for advanced validation services and digital tools that work together.

Asia-Pacific and LAMEA (not including Mexico) are becoming high-growth areas because biologics manufacturing is growing and there is more focus on quality in regulations. Countries in Asia-Pacific, such as China, India, South Korea, and Japan, are putting a lot of money into biomanufacturing capacity. This is increasing the need for validation of single-use systems, continuous processing, and outsourced CDMO services. In LAMEA, on the other hand, Brazil, Saudi Arabia, the UAE, and South Africa are gradually strengthening their biopharma sectors with the help of government programs that aim to diversify healthcare manufacturing. These areas are relying more and more on outside validation providers to meet global standards, which gives both multinational OEMs and regional specialists chances to grow their businesses.

Recent Strategies Deployed in the Market

• Jul-2025: Sartorius AG teamed up with Sensible Biotechnologies to scale up Sensible’s cell-based mRNA platform. The collaboration supports process development, GMP-compliant facility design, and global expansion, enabling clinical-grade production by 2026. This collaboration aims to advance high-quality, scalable mRNA therapeutics with superior purity and performance.
• Apr-2025: Sartorius AG announced the partnership with Mabion, providing end-to-end biopharmaceutical services from lab-scale development to large-scale manufacturing. The partnership integrates Sartorius’ cell line and upstream expertise with Mabion’s downstream optimization, validation, and GMP production, enabling faster, high-quality biologics development and streamlined access from DNA to commercial drug products.
• Dec-2024: Sartorius AG announced the establishment of is Center for Bioprocess Innovation in Marlborough, MA, offering advanced process development, optimization, and validation services. The 63,000 sq. ft. facility supports collaboration with customers and partners, accelerating novel manufacturing processes for cell and gene therapies, and will feature GMP suites for early-stage clinical production.
• Jun-2024: Thermo Fisher Scientific, Inc. unveiled biobased solutions for single-use bioprocessing containers, reducing carbon emissions in biologics manufacturing. Leveraging plant-based films certified by ISCC PLUS, these innovations maintain product consistency while supporting sustainability. The initiative also includes recycling programs, helping biopharma companies achieve environmental goals without compromising quality or efficiency.
• May-2024: Sartorius AG announced the partnership with Sanofi to co-develop an integrated continuous biomanufacturing (ICB) platform, enhancing downstream efficiency. Sartorius will leverage its hardware, consumables, and automation, while Sanofi provides R&D support. The platform integrates multiple unit operations, reduces resource use, and improves productivity, aiming to streamline global biologics manufacturing.

Bioprocess Validation Market Report Segmentation

By Mode

• In house
• Outsourced

By Stage

• Continued Process Verification
• Process Qualification
• Process Design

By Testing Type

• Bioprocess Residuals Testing
• Extractables & Leachables Testing
• Viral Clearance Testing
• Wireless and IoT Penetration Testing
• Other Testing Type

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA